APTX
Price:
$0.061
Market Cap:
$0
Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. The company is developing NYX-2925, which is in Phase II clinical development for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II/b clinical trial for treating fibromyalgia. It is also developing NYX-783, an N-methyl-D-aspartate receptors (NMDAr) modulator that is in Phase II/b clinical trial to treat post-traumatic stress disorder; and NYX-458, an NMDAr modulator, which is in Phase II clinical study for the treatment of Parkinson's di...[Read more]
Industry
Biotechnology
IPO Date
2018-06-21
Stock Exchange
NASDAQ
Ticker
APTX
According to Aptinyx Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -0.06. This represents a change of -71.49% compared to the average of -0.21 of the last 4 quarters.
The mean historical PE Ratio of Aptinyx Inc. over the last ten years is -9.16. The current -0.06 PE Ratio has changed -34.48% with respect to the historical average. Over the past ten years (40 quarters), APTX's PE Ratio was at its highest in in the December 2022 quarter at 0.19. The PE Ratio was at its lowest in in the December 2017 quarter at -17.95.
Average
-9.16
Median
-3.41
Minimum
-33.52
Maximum
-0.30
Discovering the peaks and valleys of Aptinyx Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 69.07%
Maximum Annual PE Ratio = -0.30
Minimum Annual Increase = -87.52%
Minimum Annual PE Ratio = -33.52
Year | PE Ratio | Change |
---|---|---|
2022 | -0.30 | -87.52% |
2021 | -2.41 | -29.15% |
2020 | -3.41 | 69.07% |
2019 | -2.01 | -67.87% |
2018 | -6.27 | -61.24% |
2017 | -16.18 | -51.73% |
The current PE Ratio of Aptinyx Inc. (APTX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-2.04
5-year avg
-2.88
10-year avg
-9.16
Aptinyx Inc.’s PE Ratio is less than Evelo Biosciences, Inc. (-0.00), greater than Magenta Therapeutics, Inc. (-0.15), greater than Aileron Therapeutics, Inc. (-1.83), greater than ABVC BioPharma, Inc. (-0.83), greater than Neoleukin Therapeutics, Inc. (-5.86), less than CytomX Therapeutics, Inc. (5.48), greater than Assembly Biosciences, Inc. (-2.34), greater than Instil Bio, Inc. (-2.26), greater than Nuvation Bio Inc. (-1.44), greater than Allarity Therapeutics, Inc. (-0.10), greater than NeuroBo Pharmaceuticals, Inc. (-0.87), greater than Hillstream BioPharma, Inc. (-0.99), greater than Virax Biolabs Group Limited (-0.67), greater than Quoin Pharmaceuticals, Ltd. (-0.33), less than Spero Therapeutics, Inc. (21.41), greater than Achilles Therapeutics plc (-0.64), greater than Adial Pharmaceuticals, Inc. (-0.45), greater than TransCode Therapeutics, Inc. (-0.38), less than Aditxt, Inc. (-0.00), greater than Reviva Pharmaceuticals Holdings, Inc. (-1.19), greater than Avenue Therapeutics, Inc. (-0.23),
Company | PE Ratio | Market cap |
---|---|---|
-0.00 | $28.47K | |
-0.15 | $42.44M | |
-1.83 | $53.51M | |
-0.83 | $7.12M | |
-5.86 | $8.20M | |
5.48 | $69.65M | |
-2.34 | $95.60M | |
-2.26 | $170.65M | |
-1.44 | $942.39M | |
-0.10 | $5.63M | |
-0.87 | $20.42M | |
-0.99 | $4.17M | |
-0.67 | $8.73M | |
-0.33 | $2.95M | |
21.41 | $63.24M | |
-0.64 | $43.57M | |
-0.45 | $6.47M | |
-0.38 | $6.64M | |
-0.00 | $4.82M | |
-1.19 | $38.12M | |
-0.23 | $3.84M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Aptinyx Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Aptinyx Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Aptinyx Inc.'s PE Ratio?
How is the PE Ratio calculated for Aptinyx Inc. (APTX)?
What is the highest PE Ratio for Aptinyx Inc. (APTX)?
What is the 3-year average PE Ratio for Aptinyx Inc. (APTX)?
What is the 5-year average PE Ratio for Aptinyx Inc. (APTX)?
How does the current PE Ratio for Aptinyx Inc. (APTX) compare to its historical average?